• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.伊布替尼治疗复发或难治性慢性淋巴细胞白血病患者的长期真实世界结果：瑞典同情用药队列的30个月随访
Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4.
2
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。
Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.
3
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.依鲁替尼治疗慢性淋巴细胞白血病：来自一项特定患者项目的国际经验。
Haematologica. 2018 May;103(5):e204-e206. doi: 10.3324/haematol.2017.178798. Epub 2018 Feb 1.
4
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).在波兰，用于复发/难治性慢性淋巴细胞白血病的同情用药依鲁替尼的疗效和毒性：波兰成人白血病组（PALG）分析
Leuk Lymphoma. 2017 Oct;58(10):2485-2488. doi: 10.1080/10428194.2017.1292353. Epub 2017 Feb 28.
5
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.布鲁顿酪氨酸激酶抑制剂伊布替尼（PCI-32765）在复发/难治性 B 细胞恶性肿瘤患者中具有显著的活性。
J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.
6
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.依鲁替尼治疗复发/难治性套细胞淋巴瘤：汇总分析的3.5年延长随访结果
Haematologica. 2019 May;104(5):e211-e214. doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15.
7
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.伊布替尼用于既往未治疗及复发或难治的伴有TP53畸变的慢性淋巴细胞白血病：一项2期单臂试验
Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31.
8
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.依鲁替尼可恢复一线治疗和复发/难治性慢性淋巴细胞白血病患者的免疫细胞数量和功能。
Leuk Res. 2020 Oct;97:106432. doi: 10.1016/j.leukres.2020.106432. Epub 2020 Aug 11.
9
How I manage ibrutinib-refractory chronic lymphocytic leukemia.我如何治疗依鲁替尼难治性慢性淋巴细胞白血病。
Blood. 2017 Mar 9;129(10):1270-1274. doi: 10.1182/blood-2016-09-693598. Epub 2017 Jan 17.
10
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).idelalisib联合利妥昔单抗与伊布替尼治疗复发/难治性慢性淋巴细胞白血病的疗效相当：波兰成人白血病组（PALG）的一项回顾性病例匹配研究
Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557.

引用本文的文献

1
Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study.预处理心脏科会诊对依鲁替尼治疗慢性淋巴细胞白血病疗效、毒性及结局的影响——一项KroHem研究
Cancers (Basel). 2025 Jul 10;17(14):2302. doi: 10.3390/cancers17142302.
2
Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience.伊布替尼单药治疗慢性淋巴细胞白血病的真实世界疗效：单中心经验
Med Pharm Rep. 2025 Jan;98(1):36-45. doi: 10.15386/mpr-2800. Epub 2025 Jan 31.
3
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.慢性淋巴细胞白血病治疗现代 era 中的嵌合抗原受体 T 细胞
Cancers (Basel). 2025 Jan 15;17(2):268. doi: 10.3390/cancers17020268.
4
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.3306例在临床试验之外接受依鲁替尼治疗的复发/难治性慢性淋巴细胞白血病患者的结局及预后因素：一项全国性研究
Hemasphere. 2024 Oct 8;8(10):e70017. doi: 10.1002/hem3.70017. eCollection 2024 Oct.
5
Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action.可逆共价抑制─由质量作用导致的期望共价加合物形成。
ACS Chem Biol. 2024 Apr 19;19(4):824-838. doi: 10.1021/acschembio.3c00805. Epub 2024 Apr 3.
6
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.意大利慢性淋巴细胞白血病患者使用单药伊布替尼治疗的真实世界结局：EVIDENCE研究的最终结果
Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228.
7
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.来自非干预性FIRE研究的伊布替尼治疗慢性淋巴细胞白血病患者有效性和安全性的最终结果。
Ann Hematol. 2025 Feb;104(2):1079-1093. doi: 10.1007/s00277-024-05666-3. Epub 2024 Mar 6.
8
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.中国接受 BTK 抑制剂治疗的 B 细胞淋巴增生性疾病患者的真实世界治疗模式、停药和临床结局。
Front Immunol. 2023 Jul 7;14:1184395. doi: 10.3389/fimmu.2023.1184395. eCollection 2023.
9
Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?慢性淋巴细胞白血病的 Richter 转化——我们是否取得了进展？
Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.
10
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.伊布替尼治疗慢性淋巴细胞白血病患者的真实世界临床结局和不良事件：一项单中心回顾性研究。
Medicina (Kaunas). 2023 Feb 9;59(2):324. doi: 10.3390/medicina59020324.

本文引用的文献

1
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.616 例美国伊布替尼治疗患者的毒性和结局：真实世界分析。
Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.
2
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.接受低剂量伊布替尼治疗的慢性淋巴细胞白血病（CLL）患者的可比结果：一项多中心研究的结果
Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21.
3
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.
4
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。
Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.
5
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.慢性淋巴细胞白血病患者老年评估的评价：德国慢性淋巴细胞白血病研究组CLL9试验结果
Leuk Lymphoma. 2016;57(4):789-96. doi: 10.3109/10428194.2015.1091933. Epub 2015 Oct 13.
6
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.初治和既往接受过治疗的慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）患者接受单药伊布替尼治疗的三年随访
Blood. 2015 Apr 16;125(16):2497-506. doi: 10.1182/blood-2014-10-606038. Epub 2015 Feb 19.
7
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
8
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.慢性淋巴细胞白血病诊断与治疗指南：慢性淋巴细胞白血病国际研讨会报告，更新美国国立癌症研究所工作组1996年指南
Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

作者信息

Winqvist Maria, Andersson Per-Ola, Asklid Anna, Karlsson Karin, Karlsson Claes, Lauri Birgitta, Lundin Jeanette, Mattsson Mattias, Norin Stefan, Sandstedt Anna, Rosenquist Richard, Späth Florentin, Hansson Lotta, Österborg Anders

机构信息

Department of Hematology, Karolinska University Hospital, Stockholm

Department of Oncology-Pathology, Karolinska Institutet, Stockholm.

出版信息

Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4.

DOI:10.3324/haematol.2018.198820
PMID:30514799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6518914/
Abstract
摘要